Using the industry peer median EV/EBITDA multiple (trailing + forward), Alignment Healthcare, Inc. (ALHC) has a fair value of $9.16 based on 4 comparable companies in the Medical - Healthcare Plans industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/EBITDA | Forward EV/EBITDA | |
|---|---|---|---|
| Alignment Healthcare, Inc.ALHC | 3,550 | 73.0x | 55.6x |
| Envista Holdings Corp | 3,951 | 13.0x | 13.4x |
| ICU Medical, Inc. | 3,160 | 13.0x | 13.3x |
| Privia Health Group, Inc. | 3,014 | 57.6x | 51.2x |
| Soleno Therapeutics, Inc. | 2,760 | 94.9x | 38.7x |
| Industry Median | 35.3x | 26.0x | |
| (*) EBITDA | 45 | 59 | |
| = Enterprise Value | 1,601 | 1,548 | |
| (-) Net Debt | -240 | -240 | |
| Equity Value | 1,841 | 1,788 | |
| (/) Outstanding shares | 198 | 198 | |
| Fair Price | $9 | $9 | |
Using the industry peer median EV/Revenue multiple (trailing + forward), Alignment Healthcare, Inc. (ALHC) has a fair value of $78.62 based on 8 comparable companies in the Medical - Healthcare Plans industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| Alignment Healthcare, Inc.ALHC | 3,550 | 0.8x | 0.6x |
| Oscar Health, Inc. | 5,525 | 0.3x | 0.3x |
| Mirum Pharmaceuticals, Inc. | 5,379 | 10.4x | 8.0x |
| Envista Holdings Corp | 3,951 | 1.6x | 1.7x |
| ICU Medical, Inc. | 3,160 | 1.9x | 2.0x |
| Privia Health Group, Inc. | 3,014 | 1.2x | 1.1x |
| Soleno Therapeutics, Inc. | 2,760 | 14.1x | 5.8x |
| Ultragenyx Pharmaceutical Inc. | 2,569 | 5.1x | 4.6x |
| GRAIL, Inc. | 2,528 | 16.1x | 13.2x |
| Industry Median | 3.5x | 3.3x | |
| (*) Revenue | 3,949 | 5,183 | |
| = Enterprise Value | 13,764 | 16,890 | |
| (-) Net Debt | -240 | -240 | |
| Equity Value | 14,004 | 17,130 | |
| (/) Outstanding shares | 198 | 198 | |
| Fair Price | $71 | $87 | |
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.